InterMune ascends on Esbriet sales, Phase III progress
This article was originally published in Scrip
InterMune's stock closed at its highest price this year after the company's second quarter earnings report suggested that everything finally is moving into place for the idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone).
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.